Gruppo Italiano Malattie EMatologiche dell'Adulto: Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials

The registry lists 21 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor. 3 are open to participants now and 1 have results posted.

Phase 2 7Phase 3 1Phase 4 1No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent LinesNot yet recruitingNCT07640750
• Identification of BCR::ABL1 Mutations by Digital PCR in CMLNot yet recruitingNCT07158294Not applicable
• PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingNCT06409936Phase 2
• Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous LeukemiaCompletedNCT00466726Phase 2Results posted
• Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
• Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid LeukemiaStatus unknownNCT03075969
• Bosutinib in Elderly Chronic Myeloid LeukemiaCompletedNCT02810990Phase 2
• Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownNCT02602314Phase 4
• Retrospective Evaluation of CML Patients in the National Compassionate ProgramTerminatedNCT02448095
• Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibTerminatedNCT02398825Phase 2
• LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia PatientsStatus unknownNCT02164903
• Occupational Status and Hematological DiseaseCompletedNCT02057185
• Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With DasatinibStatus unknownNCT01761890
• Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase InhibitorsStatus unknownNCT01752062
• Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01699217
• Nilotinib in PH+, BCR-, ABL+ CML PatientsCompletedNCT01535391Phase 3
• Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With NilotinibCompletedNCT01475110
• Patient Reported Outcomes in Chronic Myeloid LeukemiaCompletedNCT01252589
• Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line TherapyCompletedNCT00896129
• Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00769327Phase 2
• Nilotinib as First-line Treatment of Ph+ CML in Early Chronic PhaseCompletedNCT00481052Phase 2